CLAIMS

1. Use of a combination of a tumor necrosis factor receptor superfamily (TNFRSF) agonist ~~or a functional fragment thereof~~ and an interferon (IFN) agent ~~or a functional fragment thereof~~, for preparing a medicament for use for treating a HBV infection,

wherein the TNFRSF agonist ~~or a functional fragment thereof is~~ comprises or consists of TWEAK~~, or a functional fragment thereof~~, and

wherein the IFN agent is IFNα, IFNβ, IFNγ or IFNλ.

2. Use of a bifunctional immunostimulatory fusion protein for preparing a medicament for use for treating a HBV infection, the bifunctional immunostimulatory fusion protein comprising a tumor necrosis factor receptor superfamily (TNFRSF) agonist ~~or a functional fragment thereof~~, an interferon (IFN) agent ~~or a functional fragment thereof~~, and a linker,

wherein the TNFRSF agonist comprises or ~~a functional fragment thereof is~~consists of TWEAK, ~~or a functional fragment thereof.~~and

wherein the IFN agent is IFNα, IFNβ, IFNγ or IFNλ.

3. The use according to claim 1 or 2, wherein the IFN agent ~~or a functional fragment thereof is selected from the group consisting of a Type I IFN agent, a Type II IFN agent and a Type III IFN agent, or functional fragments thereof.~~ is IFNβ or IFNγ.

4. The use according to any one of claims 1 to 3, wherein the IFN agent ~~or a functional fragment thereof is IFNα, IFNβ, IFNγ or IFNλ, or functional fragments thereof~~is IFNβ.

5. The use according to ~~any one of claims~~claim 1 ~~to 4~~or 2, wherein the IFN agent ~~or a functional fragment thereof is IFNβ or IFNγ, or functional fragments thereof.~~

~~6. The use according to any one of claims 1 to 5, wherein the IFN agent or a functional fragment thereof is IFNβ, or a functional fragment thereof.~~

~~7. The use according to any one of claims 1 to 4, wherein the IFN agent or a functional fragment thereof is~~ is IFNα~~, or a functional fragment thereof~~.

~~8~~6. The use according to any one of claims 1 or 3 to ~~7~~5, wherein the TNFRSF agonist ~~or a functional fragment thereof~~ and the IFN agent ~~or a functional fragment thereof~~ are comprised in a single pharmaceutical composition.

~~9~~7. The use according to any one of claims 1 or 3 to ~~7~~5, wherein the TNFRSF agonist ~~or a functional fragment thereof~~ and the IFN agent ~~or a functional fragment thereof~~ are comprised in distinct pharmaceutical compositions.

8. The use according to any one of claims 1 to 7, wherein the TNFRSF agonist is TWEAK or a fusion protein comprising TWEAK.

9. The use according to claim 8, wherein the fusion protein comprising TWEAK is Ig-TWEAK.

10. The use according to claim 8 or 9, wherein TWEAK is represented by SEQ ID NO: 3.

11. The use according to any one of claims 2 to ~~7~~5, wherein the linker is a peptide linker incorporating a multimerization domain.

~~11~~12. The use according to claim ~~10~~11, wherein the multimerization domain is selected among a tenascin trimerization motif, a collectin trimerization domain, streptavidin, an IgE heavy-chain domain 2 (EHD2), an IgM heavy-chain domain 2 (MHD2), an IgG heavy-chain domain 3 (GHD3), an IgA heavy-chain domain 3 (AHD2), an IgD heavy-chain domain 3 (DHD3), an IgE heavy-chain domain 4 (EHD4), an IgM heavy-chain domain 4 (MHD4), an Fc domain, an uteroglobin dimerization domain and a leucine zipper (LZ) domain.

~~12~~13. A pharmaceutical composition comprising:

a TNFRSF agonist ~~or a functional fragment thereof~~; and

an interferon (IFN) agent ~~or a functional fragment thereof~~

wherein the TNFRSF agonist ~~or a functional fragment thereof is~~ comprises or consists of TWEAK, ~~or a functional fragment thereof.~~and

~~13~~wherein the IFN agent is IFNα, IFNβ, IFNγ or IFNλ.

14. A pharmaceutical composition comprising a bifunctional immunostimulatory fusion protein comprising a tumor necrosis factor receptor superfamily (TNFRSF) agonist ~~or a functional fragment thereof~~, an interferon (IFN) agent ~~or a functional fragment thereof~~, and a linker,

wherein the TNFRSF agonist comprises or ~~a functional fragment thereof is~~ consists of TWEAK, and

wherein the IFN agent is IFNα, IFNβ, IFNγ or ~~a functional fragment thereof~~IFNλ.

~~14~~15. A combination of a tumor necrosis factor receptor superfamily (TNFRSF) agonist ~~or a functional fragment thereof~~ and an interferon (IFN) agent ~~or a functional fragment thereof~~, for use for treating a HBV infection,

wherein the TNFRSF agonist ~~or a functional fragment thereof is~~ comprises or consists of TWEAK, ~~or a functional fragment thereof.~~and

~~15~~wherein the IFN agent is IFNα, IFNβ, IFNγ or IFNλ.

16. A bifunctional immunostimulatory fusion protein comprising a tumor necrosis factor receptor superfamily (TNFRSF) agonist ~~or a functional fragment thereof~~, an interferon (IFN) agent ~~or a functional fragment thereof~~, and a linker, for use for treating a HBV infection,

wherein the TNFRSF agonist comprises or ~~a functional fragment thereof is~~ consists of TWEAK, and

wherein the IFN agent is IFNα, IFNβ, IFNγ or ~~a functional fragment thereof~~IFNλ.

~~16~~17. The pharmaceutical composition according to claims ~~12~~13 or ~~13~~14, the combination according to claim ~~14~~15 or the bifunctional immunostimulatory fusion protein according to claim ~~15~~16, wherein the IFN agent is according to any one of claims 3 to ~~7~~5.

18. The pharmaceutical composition according to claims 13 or 14, the combination according to claim 15 or the bifunctional immunostimulatory fusion protein according to claim 16, wherein the TNFRSF agonist is according to any one of claims 8 to 10.

5